戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lower lid retraction in patients with Graves ophthalmopathy.
2 king increases the risk and relapse rate for ophthalmopathy.
3 a major controllable risk factor for thyroid ophthalmopathy.
4 is for the immunologic attack seen in Graves ophthalmopathy.
5 g to the clinical findings typical of Graves ophthalmopathy.
6 sociated with the appearance or worsening of ophthalmopathy.
7 sic questions about the treatment of thyroid ophthalmopathy.
8 intense inflammation associated with Graves' ophthalmopathy.
9 te the underlying autoimmune pathogenesis of ophthalmopathy.
10  The procedure was also effective in thyroid ophthalmopathy.
11  in patients with active, moderate-to-severe ophthalmopathy.
12                           Thyroid-associated ophthalmopathy, a condition commonly associated with Gra
13                           Thyroid-associated ophthalmopathy and dermopathy are connective tissue mani
14                  The pathogenesis of thyroid ophthalmopathy and its relation to thyroid gland dysfunc
15  in the etiology and pathobiology of Graves' ophthalmopathy and/or other ocular myopathies.
16 of >/=3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in propt
17       Although the European Group on Graves' Ophthalmopathy (EUGOGO) recommend intravenous methylpred
18 men who exhibit higher rates for most of the ophthalmopathies, excluding uveitis.
19                                      Graves' ophthalmopathy (GO) affects 50% to 60% of patients with
20 l fat decompression in patients with Graves' ophthalmopathy (GO) by measuring their midpupil lid dist
21 phy (OCTA) in patients with inactive Graves' ophthalmopathy (GO) compared with healthy controls by pe
22 rs, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not been established convincingl
23      Appearances of and increases in Graves' ophthalmopathy (GO) have been reported after treatment o
24                                       Graves ophthalmopathy (GO) is an autoimmune disease that typica
25 a serious threatening vision loss in Graves' ophthalmopathy (GO).
26 (GD) is a common thyroid disease, and Graves ophthalmopathy(GO) is the most common extra-thyroidal ma
27            The surgical management of Graves ophthalmopathy includes treatment of globe malposition (
28 se undergoing the orbital changes of Graves' ophthalmopathy is often challenging, even as our underst
29 onnective tissues seen in thyroid-associated ophthalmopathy is unknown.
30         Stickler syndrome (hereditary arthro-ophthalmopathy) is the commonest inherited cause of reti
31 ations, for example, Duane syndrome, Graves' ophthalmopathy, may be particularly problematic.
32 e patients had moderate, symptomatic Graves' ophthalmopathy (mean clinical activity score, 6.2) but n
33 on (n = 6), orbital decompression for Graves ophthalmopathy (n = 3), dacryocystorhinostomy (n = 1), a
34                              The restrictive ophthalmopathy of TAO may be associated with more sustai
35                                  The Graves' Ophthalmopathy Quality of Life (GO-QOL) scale was comple
36 ate, and a larger improvement in the Graves' Ophthalmopathy Quality of Life overall score.
37 tions only extending to patients with Graves ophthalmopathy, selenium supplementation is widely used
38  mean change in overall score on the Graves' ophthalmopathy-specific quality-of-life (GO-QOL) questio
39 l Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life questionnaire.
40                           Thyroid-associated ophthalmopathy (TAO) is a common and debilitating manife
41                           Thyroid associated ophthalmopathy (TAO) is a common autoimmune condition af
42                           Thyroid-associated ophthalmopathy (TAO) represents a disfiguring and potent
43 ed in the pathogenesis of thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves
44                           Thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves'
45 ed in the pathogenesis of thyroid-associated ophthalmopathy (TAO), the orbital manifestation of GD, r
46 ue remodeling linked with thyroid-associated ophthalmopathy (TAO).
47  This process is known as thyroid-associated ophthalmopathy (TAO).
48 ity of the human orbit to thyroid-associated ophthalmopathy (TAO).
49 c markers for more severe thyroid-associated ophthalmopathy (TAO).
50 le in the pathogenesis of thyroid-associated ophthalmopathy (TAO).
51                      In patients with active ophthalmopathy, teprotumumab was more effective than pla
52 vement of the extraocular muscles in Graves' ophthalmopathy, the absence of N-CAM expression on other
53  fat accumulation, such as occurs in Graves' ophthalmopathy, tissue fibrosis, abnormal wound healing,
54  suggests that it may play a role in thyroid ophthalmopathy treatment and prevention.
55 retrospective review of patients with Graves ophthalmopathy undergoing lower eyelid retraction surger
56 al, specific diagnostic criteria for thyroid ophthalmopathy were established and are included in this
57 Medical records for patients with dysthyroid ophthalmopathy who underwent bilateral lateral rectus re